EXPOSURE-RESPONSE CHARACTERISTICS AND PREDICTORS OF EFFICACY IN MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS PATIENTS RECEIVING TOFACITINIB.

被引：0
|
作者：
Hutmacher, M. M. [1 ]
Papp, K. A. [2 ]
Lebwohl, M. [3 ]
Ito, K. [4 ]
Tan, H. [4 ]
Wolk, R. [4 ]
Mebus, C. [4 ]
Rottinghaus, S. [4 ]
Valdez, H. [5 ]
Krishnaswami, S. [4 ]
Gupta, P. [4 ]
机构：
[1] Ann Arbor Pharmacometr Grp A2PG, Ann Arbor, MI USA
[2] Prob Med Res & K Papp Clin Res Inc, Waterloo, ON, Canada
[3] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY 10029 USA
[4] Pfizer Inc, Groton, CT 06340 USA
[5] Pfizer Inc, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2016年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI-082
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] Exploring the synergistic effects of cytokines as predictors of response to apremilast in patients with moderate to severe plaque psoriasis
    Garcet, S.
    Correa-da Rosa, J.
    Nograles, K.
    Schafer, P.
    Krueger, J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S42 - S42
  • [22] Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
    Valenzuela, F.
    Korman, N. J.
    Bissonnette, R.
    Bakos, N.
    Tsai, T. -F.
    Harper, M. K.
    Ports, W. C.
    Tan, H.
    Tallman, A.
    Valdez, H.
    Gardner, A. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (04) : 853 - 862
  • [23] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
    Merola, Joseph
    Tatulych, Svitlana
    Kaur, Mandeep
    Lan, Shuping
    Mallbris, Lotus
    Mamolo, Carla
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
  • [24] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis
    Kaur, M.
    Merola, J.
    Tatulych, S.
    Mamolo, C.
    Lan, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 81 - 81
  • [25] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
    Merola, Joseph
    Tatulych, Svitlana
    Mamolo, Carla
    Lan, Shuping
    Mallbris, Lotus
    Kaur, Mandeep
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
  • [26] EFFICACY OF ADALIMUMAB PLUS METHOTREXATE IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS
    Rokni, Ghasem Rahmatpour
    Goldust, Mohamad
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 10 - 10
  • [27] Efficacy of PUVA therapy compared with biologics in moderate to severe chronic plaque psoriasis
    Inzinger, Martin
    Heschl, Bettina
    Weger, Wolfgang
    Hofer, Angelika
    Legat, Franz Josef
    Gruber-Wackernagel, Alexandra
    Salmhofer, Wolfgang
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S55 - S55
  • [28] Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis
    Zhou, Honghui
    Zhu, Yaowei
    Lu, Ming
    Hu, Chuanpu
    Liao, Sam
    Yeilding, Newman
    Davis, Hugh M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1112 - 1112
  • [29] Population-Based Exposure-Efficacy Modeling of Ustekinumab in Patients With Moderate to Severe Plaque Psoriasis
    Zhou, Honghui
    Hu, Chuanpu
    Zhu, Yaowei
    Lu, Ming
    Liao, Sam
    Yeilding, Newman
    Davis, Hugh M.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (03): : 257 - 267
  • [30] Clinical factors predicting the therapeutic response to ustekinumab in patients with moderate to severe chronic plaque psoriasis
    Hwang, Young Ji
    Youn, Sang Woong
    Kim, Bo Ri
    Yu, Dae Young
    Kim, Youngdoe
    Pires, Antonio
    Cho, Soyun
    Seo, Seong Jun
    Lee, Eun So
    Roh, Joo Young
    Choi, Gwang Seong
    Lee, Min Geol
    JOURNAL OF DERMATOLOGY, 2017, 44 (05): : 560 - 566
12345